$艾伯维公司(ABBV)$ 表示，终止ABBV-154的开发工作。

TNFα-新型糖皮质激素受体调节剂。还是安全性/副作用方面的考量。

it did exactly what we thought it would do from the standpoint of efficacy,” AbbVie CEO Rick Gonzalez said during the first-quarter earnings call. “But it did it in a way only at the highest dose, and at that highest dose we did see … some effects of steroids on some of the biomarkers. And based on the way we think regulators would look at a label for those kinds of products, we didn’t believe that would be a competitive profile.”